Does Early Chemotherapy Improve Survival in Advanced Endometrial Cancer?
Authors:
- 4 October 2019
- journal article
- research article
- Published by Wolters Kluwer Health in American Journal of Clinical Oncology
- Vol. 42 (11) , 813-817
Abstract
Objectives: In endometrial cancer, the appropriate sequence of adjuvant chemotherapy (aCT) and adjuvant radiation therapy (aRT) is unclear. We aim evaluated whether early chemotherapy is associated with improved overall survival (OS) and cancer-specific survival (CSS). Methods: Endometrial cancer patients that received aCT and aRT were selected from the SEER-Medicare database. Early chemotherapy was defined as receiving aCT before aRT, with or without additional aCT (“sandwich” regimens). All other patients received a full course of aRT before chemotherapy with or without concurrent chemotherapy. Univariate and multivariate Cox proportional hazards regression was utilized to assess the impact of clinical and demographic factors on OS. Results: We selected 597 patients for analysis. Median age and was 72 years; 85% of patients were white. Overall, 68% of women had FIGO (International Federation of Gynecology and Obstetrics) stage III disease and 77% received 4 to 6 cycles of chemotherapy. Five-year OS (66.6% vs. 62.4%, P=0.46) and 5-year CSS (71.1% vs. 71.2%, P=0.88) was not significantly improved among those receiving early chemotherapy. In addition, early chemotherapy did not improve OS (hazard ratio [HR]=0.87; 95% confidence interval [CI]: 0.56-1.34, P=0.53) or CSS (HR=1.21; 95% CI: 0.82-1.79, P=0.34) on multivariate analysis. Compared with 1 to 3 cycles, receiving 4 to 6 (HR=0.48, 95% CI: 0.26-0.87, P=0.02), and ≥7 cycles (HR=0.42, 95% CI: 0.20-0.89, P=0.02) of chemotherapy was associated with improved OS. Conclusion: No differences in OS or CSS were noted among endometrial patients receiving early chemotherapy. However, the number of chemotherapy cycles was associated with prolonged survival.Keywords
This publication has 19 references indexed in Scilit:
- Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: A Japanese Gynecologic Oncology Group studyGynecologic Oncology, 2008
- Adjuvant chemotherapy vs radiotherapy in high-risk endometrial carcinoma: results of a randomised trialBritish Journal of Cancer, 2006
- Adjuvant whole abdominal irradiation in clinical stages I and II papillary serous or clear cell carcinoma of the endometrium: A phase II study of the Gynecologic Oncology GroupGynecologic Oncology, 2006
- Randomized Phase III Trial of Whole-Abdominal Irradiation Versus Doxorubicin and Cisplatin Chemotherapy in Advanced Endometrial Carcinoma: A Gynecologic Oncology Group StudyJournal of Clinical Oncology, 2006
- Treatment of high-risk uterine cancer with whole abdominopelvic radiation therapyInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2000
- Pathologic stage III endometrial carcinoma. Prognostic factors and patterns of recurrenceCancer, 1993
- Adjuvant whole abdominopelvic irradiation for high risk endometrial carcinomaInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 1991
- Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: A gynecologic oncology group studyGynecologic Oncology, 1991
- Surgical pathologic spread patterns of endometrial cancer: A gynecologic oncology group studyCancer, 1987
- Results of therapy, analysis of failures, and prognostic factors for clinical and pathologic stage III adenocarcinoma of the endometriumGynecologic Oncology, 1987